Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Aleksander L. Chojecki"'
Autor:
Thomas G. Knight, Melissa Aguiar, Myra Robinson, Allison Morse, Tommy Chen, Rupali Bose, Jing Ai, Brittany K. Ragon, Aleksander L. Chojecki, Nilay A. Shah, Srinivasa R. Sanikommu, James Symanowski, Edward A. Copelan, Michael R. Grunwald
Publikováno v:
JCO Oncology Practice. 18:e1494-e1504
PURPOSE: Patients with hematologic malignancies are extremely vulnerable to financial toxicity (FT) because of the high costs of treatment and health care utilization. This pilot study identified patients at high risk because of FT and attempted to i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a89dd1ce38b1e48f4debe3dc157bc215
https://doi.org/10.1200/op.22.00056
https://doi.org/10.1200/op.22.00056
Autor:
Brittany Knick Ragon, Danielle Boselli, Rupali Bose, Stephanie Begley, Melissa Aguiar, Kris Blackley, Nilay A. Shah, Aleksander L. Chojecki, Srinivasa Reddy R. Sanikommu, Jing Ai, Lawrence J Druhan, Nury M Steuerwald, Jai N Patel, James T. Symanowski, Belinda R. Avalos, Edward A. Copelan, Derek Raghavan, Thomas G. Knight, Michael R. Grunwald
Publikováno v:
Blood. 140:10993-10995
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2c54ec969f6f5779ed47a647d708b17f
https://doi.org/10.1182/blood-2022-159179
https://doi.org/10.1182/blood-2022-159179
Autor:
Aleksander L. Chojecki, Jai N. Patel, David M Foureau, James Symanowski, Xhevahire Begic, Michael Davis, Nury M Steuerwald, Sarah Norek, Srinivasa Reddy R. Sanikommu, Nilay A. Shah, Brittany Knick Ragon, Thomas G. Knight, Jing Ai, Michael R. Grunwald, Nilanjan Ghosh, Lawrence J Druhan, Belinda R. Avalos, Edward A. Copelan
Publikováno v:
Blood. 140:10534-10536
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::923bc3be43ff0db9416e4333f266bd2b
https://doi.org/10.1182/blood-2022-160214
https://doi.org/10.1182/blood-2022-160214
Autor:
Aleksander L. Chojecki, Kristyn Y. DiSogra, Justin Arnall, Nicole Cowgill, Amy Soni, Charles H. Packman, Srinivasa Reddy Sanikommu, Nilay A. Shah, Brittany K. Ragon, Thomas G. Knight, Jing Ai, Belinda R. Avalos, Edward A. Copelan, Michael R. Grunwald
Publikováno v:
Leukemia & Lymphoma. 63:1515-1517
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fc40ab107f6774b022f9671ebced6f5f
https://doi.org/10.1080/10428194.2022.2032037
https://doi.org/10.1080/10428194.2022.2032037
Autor:
Thomas G. Knight, James T. Symanowski, Jing Ai, Brittany Knick Ragon, Aleksander L. Chojecki, Nilay A. Shah, Srinivasa Reddy Sanikommu, Edward A. Copelan, Declan Walsh, Michael R. Grunwald, Patrick L Meadors
Publikováno v:
Blood. 140:8144-8145
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f5c59e2daf42986883fdeab776399b6c
https://doi.org/10.1182/blood-2022-168973
https://doi.org/10.1182/blood-2022-168973
Autor:
Rushil V. Patel, Danielle Boselli, Patrick L Meadors, Stephanie Begley, Rupali Bose, Jing Ai, Brittany Knick Ragon, Srinivasa Reddy R. Sanikommu, Nilay A. Shah, Thomas G. Knight, James T. Symanowski, Declan Walsh, Michael R. Grunwald, Aleksander L. Chojecki
Publikováno v:
Blood. 140:5279-5280
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e0600b5c0bd85f1c874537de995edc2b
https://doi.org/10.1182/blood-2022-156494
https://doi.org/10.1182/blood-2022-156494
Autor:
Jing Ai, Brittany K. Ragon, Srinivasa R. Sanikommu, Michael R. Grunwald, Edward A. Copelan, Kristyn Y. DiSogra, Thomas G. Knight, Nilay A. Shah, Ariel Denson, Belinda R. Avalos, Aleksander L. Chojecki, Justin Arnall
Publikováno v:
Blood. 136:14-17
Introduction Gleevec, Imatinib mesylate, is the first in class BCR-ABL tyrosine kinase inhibitor initially approved to treat CML. In February 2016, generic imatinib products became available. As generic products are not required to offer comparative
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a73af1ff6eba0248f64002bfa3993fc0
https://doi.org/10.1182/blood-2020-137250
https://doi.org/10.1182/blood-2020-137250
Autor:
Aleksander L, Chojecki, Justin, Arnall, Danielle, Boselli, Rushil, Patel, Zane, Chiad, Kristyn Y, DiSogra, Allison, Karabinos, Tommy, Chen, Adilen, Cruz, Allison, Verbyla, Jing, Ai, Thomas G, Knight, Brittany K, Ragon, Nilay A, Shah, Srinivasa R, Sanikommu, James, Symanowski, Belinda R, Avalos, Edward A, Copelan, Michael R, Grunwald
Publikováno v:
Leukemia Research. 119:106904
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::90a2efa40498f2dc6f67abe8a31cdbbf
https://doi.org/10.1016/j.leukres.2022.106904
https://doi.org/10.1016/j.leukres.2022.106904
Autor:
Kris Blackley, Thomas Batchelor, Zainab Shahid, Ben Masten, Belinda R. Avalos, Edward A. Copelan, Thomas G. Knight, Laura W. Musselwhite, Jing Ai, Aleksander L. Chojecki, Michael R. Grunwald, Ashley Sumrall, Tamara K. Moyo, Stephanie Murphy, Carly Rivet, Nilay A. Shah, Armida Parala-Metz, Laura Kabrich, Jean Chai, Kelly A. Leonard, Ifeyinwa Osunkwo, Brittany K. Ragon, Declan Walsh, Srinivasa R. Sanikommu, Brian Kersten, Beth York
Publikováno v:
Blood
Background: Patients (pts) with malignancies are at increased risk of morbidity and mortality from COVID-19. Among these pts, some of the higher case fatality ratios (CFR) reported are among pts with myeloid malignancies, ranging from 37 to 50% (Meht
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7364f149f3643a04278fb50723e43d0c
http://europepmc.org/articles/PMC8701538
http://europepmc.org/articles/PMC8701538
Autor:
Brittany K. Ragon, Belinda R. Avalos, Allison Karabinos, Kristyn Y. DiSogra, Jing Ai, Danielle Boselli, Edward A. Copelan, James T. Symanowski, Michael R. Grunwald, Nilay A. Shah, Aleksander L. Chojecki, Justin Arnall, Tommy Chen, Thomas G. Knight, Srinivasa R. Sanikommu
Publikováno v:
Blood. 138:1252-1252
Introduction: Treatment options for newly diagnosed patients (pts) with acute myeloid leukemia (AML) have historically been limited. The combination of a hypomethylating agent and venetoclax (HMA/Ven) has emerged as standard of care treatment for eld
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::16f358ddf05b869b3431d32f0c63348c
https://doi.org/10.1182/blood-2021-149811
https://doi.org/10.1182/blood-2021-149811